Chemotherapy最新文献

筛选
英文 中文
Primary squamous cell carcinoma of the duodenum: a case report and literature review. 十二指肠原发性鳞状细胞癌:病例报告和文献综述。
IF 2 4区 医学
Chemotherapy Pub Date : 2024-11-11 DOI: 10.1159/000542485
Yifan Hui, Fei Ke, Wei Lu, Wenli Qiu, Xia Zheng, Haibo Cheng
{"title":"Primary squamous cell carcinoma of the duodenum: a case report and literature review.","authors":"Yifan Hui, Fei Ke, Wei Lu, Wenli Qiu, Xia Zheng, Haibo Cheng","doi":"10.1159/000542485","DOIUrl":"https://doi.org/10.1159/000542485","url":null,"abstract":"<p><p>Duodenal squamous cell carcinoma is an exceedingly rare occurrence among gastrointestinal malignancies, and its diagnosis and treatment are not well understood. In this report, we present a case of duodenal squamous cell carcinoma with liver and adrenal metastasis. The patient was treated with gemcitabine and S-1, achieving a progression-free survival (PFS) of 7 months and an overall survival (OS) of 9 months. Additionally, we review the features and treatment approaches reported in previous cases of primary duodenal carcinoma. Clearly, further case reports, such as ours, can contribute to a deeper understanding that is essential for characterizing this entity and establishing management guidelines.</p>","PeriodicalId":10047,"journal":{"name":"Chemotherapy","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting reprisal of solid cancer treatment and 60-month survival after Medical Intensive Care. A single-centre cohort study. 预测对实体癌治疗的报复和医疗重症监护后 60 个月的生存率。单中心队列研究。
IF 2 4区 医学
Chemotherapy Pub Date : 2024-11-09 DOI: 10.1159/000542101
Victoria Ferrari, Lucas Morand, Hervé Hyvernat, Renaud Schiappa, Jean Dellamonica, Nihal Martis
{"title":"Predicting reprisal of solid cancer treatment and 60-month survival after Medical Intensive Care. A single-centre cohort study.","authors":"Victoria Ferrari, Lucas Morand, Hervé Hyvernat, Renaud Schiappa, Jean Dellamonica, Nihal Martis","doi":"10.1159/000542101","DOIUrl":"https://doi.org/10.1159/000542101","url":null,"abstract":"<p><strong>Introduction: </strong>Our study aimed to identify relevant features associated with the reprisal of antineoplastic treatment in patients with solid cancers after unplanned admittance to the intensive care unit (ICU) and to assess 60th-month survival in patients with solid neoplasms admitted to the ICU.</p><p><strong>Methods: </strong>This single-centre retrospective study of critically ill patients with active cancers was performed over a 13-year period (2005-2018). Patients' characteristics, overall survival and antineoplastic treatment reprisal were extracted from digital medical files and compared.</p><p><strong>Results: </strong>134 patients were included in the study. Solid neoplasms were mostly localised to the head and neck (n=53) followed by lung cancers (n=29). Sepsis was the leading cause of ICU admission (62.1%) with 41/82 patients presenting with septic shock. Antineoplastic treatments were resumed in 40 patients. An age ≤60 years and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1 were found to be predictors for treatment reprisal, with odd ratios of, respectively, 2.83 (95%CI, 1.15-6.99) and 5.45 (95%CI, 2.01-14.82); area under the ROC curve of 72% (95%CI, 63-81%). Survival after the immediate discharge from the ICU was 101/134 (75%) and the 60-month survival rate was 29% and significantly higher in the treatment-reprisal group.</p><p><strong>Conclusions: </strong>Age and ECOG PS were found to be predictors for treatment reprisal in patients with solid neoplasms admitted to the ICU. The latter benefit from better long-term survival.</p>","PeriodicalId":10047,"journal":{"name":"Chemotherapy","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信